Evidence map›Paper›PMID 41136408›Full record

ArticleNPJ breast cancer2025

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.

Masahiro Takada, Shigehira Saji, Takayuki Ueno, Norikazu Masuda, Hiroshi Ishiguro, Takanori Ishida, Toshiaki Saeki, Shigeru Imoto, Shinji Ohno, Hiroji Iwata and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Masahiro TakadaDepartment of Breast Surgery, Kansai Medical University, Hirakata, Japan.ORCID http://orcid.org/0000-0002-5954-1296
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Takayuki UenoBreast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9080-9377
Norikazu MasudaDepartment of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0002-7302-0278
Hiroshi IshiguroBreast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Japan.
Takanori IshidaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Toshiaki SaekiBreast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Japan.
Shigeru ImotoDepartment of Breast Surgery, Kyorin University School of Medicine, Mitaka, Japan.
Shinji OhnoDepartment of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan.
Hiroji IwataGraduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Tomoharu SugieDepartment of Breast Surgery, Kansai Medical University, Hirakata, Japan.
Kenjiro AogiDepartment of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Shin TakayamaDepartment of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan.
Nobuaki SatoDepartment of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
Yuichiro KaiUeo Breast Cancer Hospital, Oita, Japan.
Masahiro KitadaBreast Disease Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
Rikiya NakamuraDivision of Breast Surgery, Chiba Cancer Center, Chiba, Japan.
Kenichi WatanabeDepartment of Breast Surgery, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan.
Yutaka MatsuyamaDepartment of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Masakazu ToiTokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. masakazu_toi@tmhp.jp.ORCID http://orcid.org/0000-0003-1488-9958

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This multicenter observational study investigated the prognosis of patients who participated in the Phase III POTENT trial, which examined combining S-1 with standard endocrine therapy in patients with estrogen receptor-positive, HER2-negative early breast cancer, over a longer follow-up period. The primary endpoint was overall survival (OS), with invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) as secondary endpoints. Of the 1,930 POTENT trial participants, 1,593 patients (790 for S-1 and 803 for endocrine therapy alone) were included here. The median follow-up time was 77.5 months. Fifty-one and 58 deaths were observed in the S-1 and endocrine therapy alone groups, respectively. The 6-year OS rates were similar, with 94.4% in the S-1 group and 93.1% in the endocrine therapy alone group. Overall, both endocrine therapy alone and endocrine therapy plus S-1 resulted in favorable OS. Combining S-1 with endocrine therapy maintained the previously observed benefits of IDFS and DDFS.

Identifiers

PMID41136408
PMCPMC12552499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.